Targets › NTRK1
11 programs from 11 companies in 37 trials: 19 Phase 2, 9 Phase 1, 7 Phase 3, 2 Phase 4; Oncology, Neurology, Immunology; next expected readout Jan 2027.
Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand. (UniProt, P04629)
Open in Phaseline: the race on NTRK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Entrectinib (RXDX-101) Neurotrophic tyrosine kinase receptor inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; ALK tyrosine kinase receptor inhibitor | NTRK1, NTRK2, NTRK3, ROS1, ALK | Phase 3 | Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Breast Cancer; Solid Tumors … | Jan 2027 |
| Bristol-Myers Squibb | Repotrectinib Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor | NTRK1, NTRK2, ROS1, NTRK3, CD74 | Phase 3 | Carcinoma, Non-Small-Cell Lung | Feb 2027 |
| Nuvation Bio | Taletrectinib Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor | ROS1, NTRK1, NTRK2, NTRK3 | Phase 3 | Non Small Cell Lung Cancer; Non-small Cell Lung Cancer (NSCLC) | Jun 2027 |
| Dompé Farmaceutici | Cenegermin Neurotrophic tyrosine kinase receptor agonist | NTRK1, NTRK2, NTRK3 | Phase 3 | Non-Arteritic Anterior Ischemic Optic Neuropathy; Persistent Corneal Epithelial Defect; Dry Eye | Sep 2027 |
| Benedetto Falsini | CHF6467 Nerve growth factor (NGF) agonist; binds trkA (NTRK1) receptor with high affinity and p75N | NGFR, NTRK1 | Phase 2 | Optic Pathway Glioma | Jun 2027 |
| Teligene US | TL118 NTRK fusion inhibitor | NTRK1, NTRK2, NTRK3 | Phase 2 | Solid Tumor | Dec 2027 |
| Xuanzhu Biopharmaceutical | XZP-5955 tablets NTRK and ROS1 fusion inhibitor | NTRK1, NTRK2, NTRK3, ROS1 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Jun 2027 |
| Turning Point Therapeutics | Repotrectinib (TPX-0005) Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor | NTRK1, NTRK2, ROS1, NTRK3, CD74 | Phase 1 | Locally Advanced Solid Tumors; NSCLC; NSCLC Stage IV; Advanced Cancer | Sep 2027 |
| VM Oncology | VMD-928 TrkA inhibitor | NTRK1 | Phase 1 | Head and Neck Carcinoma | Dec 2027 |
| Cullgen (Shanghai),Inc | CG001419 NTRK inhibitor | NTRK1, NTRK2, NTRK3 | Phase 1 | Solid Tumors Harboring NTRK Fusion | Aug 2030 |
| Bayer | Larotrectinib (BAY2757556) Neurotrophic tyrosine kinase receptor inhibitor | NTRK1, NTRK2, NTRK3 | Phase 1 | Solid Tumors Harboring NTRK Fusion; Advanced Malignant Solid Neoplasm; Advanced Lymphoma; Central Nervous System Neoplasm … | – |
Non Small Cell Lung Cancer (3) Non-Small Cell Lung Cancer (2) Carcinoma, Non-Small-Cell Lung (2) Solid Tumors (2) Haematological Malignancy (2) Solid Tumors Harboring NTRK Fusion (2) Locally Advanced Solid Tumors (2) Locally Advanced or Metastatic Solid Tumors (1) Non-Arteritic Anterior Ischemic Optic Neuropathy (1) Persistent Corneal Epithelial Defect (1) Dry Eye (1) Non-small Cell Lung Cancer (NSCLC) (1)
small molecule (9), protein or peptide (1), mixed (1)
Xuanzhu Biopharmaceutical (1) Dompé Farmaceutici (1) Nuvation Bio (1) Roche (1) Cullgen (Shanghai),Inc (1) Turning Point Therapeutics (1) Bristol-Myers Squibb (1) VM Oncology (1) Benedetto Falsini (1) Teligene US (1) Bayer (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.